Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sergey, Semochkin"'
Autor:
Sergey Semochkin
Publikováno v:
Russian journal of hematology and transfusiology. 67:240-260
Introduction. Immunomodulatory drugs (IMiDs) are a class of chemical derivatives of thalidomide with numerous immunomodulatory, antiangiogenic, anti-inflammatory, and cytostatic effects in multiple myeloma (MM).Aim — to highlight the history of the
Autor:
Sergey Semochkin
Publikováno v:
Meditsinskiy sovet = Medical Council.
Anemia is one of the most common symptoms of hematological malignancy and, on the other hand, a common complication of myelosuppressive anticancer therapy. Iron, vitamin B12, folate, biological analogs of human erythropoietin (EPO), and new targeted
Autor:
Stéphane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Jörg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Döhner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo
Publikováno v:
Scientia
Enasidenib; Conventional care Enasidenib; Atenció convencional Enasidenib; Atención convencional This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3715a5d50e378580e2588f9f261b90de
https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60
https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60
Autor:
Stéphane, de Botton, Pau, Montesinos, Andre, Schuh, Cristina, Papayannidis, Paresh, Vyas, Andrew H, Wei, Hans Beier, Ommen, Sergey, Semochkin, Hee-Je, Kim, Richard A, Larson, Jamie, Koprivnikar, Olga, Frankfurt, Felicitas R, Thol, Jörg, Chromik, Jenny L, Byrne, Arnaud, Pigneux, Xavier, Thomas, Olga, Salamero, María-Belén, Vidriales, Vadim A, Doronin, Hartmut, Döhner, Amir T, Fathi, Eric, Laille, Xin, Yu, Maroof, Hasan, Patricia, Martín-Regueira, Courtney D, DiNardo
Publikováno v:
Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 inhibitor, with conventional care regimens (CCR) in patients aged =60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f5721a519b6f1e60c6aafec14ec22139
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16620
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16620
Autor:
Miklos Egyed, Jennie Zhang, Anna Schuh, Andrey Zaritskey, Asher Chanan-Khan, Samuel Vokurka, Brendan Purse, Sergey Semochkin, David Simpson, Jeannine Kassis, Robin Foà
Publikováno v:
The Lancet. Haematology. 4(11)
The efficacy and safety of lenalidomide as maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic leukaemia is unknown. Although kinase inhibitors can improve outcomes for some patients with relapsed and
Publikováno v:
Europe PubMed Central
The myelodysplastic syndromes (MDS) are a distinct group of clonal disorders of hematopoietic stem or progenitor cells characterized by ineffective hematopoiesis and peripheral cytopenias. The data on the epidemiology of MDS in Russia are absent.The
Autor:
David Simpson, Robin Foà, Miklos Egyed, Asher Chanan-Khan, Brendan Purse, Andrey Zaritskey, Sergey Semochkin, Jeannine Kassis, Samuel Vokurka, Anna Schuh, Jennie Zhang
Publikováno v:
ResearcherID
Introduction: Despite recent advances in available treatments, chronic lymphocytic leukemia (CLL) remains an incurable disease, and the vast majority of patients (pts) will relapse and require additional lines of therapy. Thus, prolonging remission i
Autor:
Sergey Semochkin, Mariya Gennadyevna Pavlova, V M Sotnikov, Yuliya Petrovna Sych, Roman Alekseevich Parkhomenko, Ekaterina Ivanovna Bobrova, Nadezhda Mazerkina, Valentin V. Fadeyev, Olga Zheludkova
Publikováno v:
Клиническая и экспериментальная тиреоидология, Vol 10, Iss 3, Pp 45-52 (2014)
Aim The aim of our study was to analyze thyroid status in adults after treatment for malignancies in childhood and its relationship with dose and type of radiotherapy. Material and methods Thyroid function (TSH, free T4, anti-TPO), thyroid ultrasound
Publikováno v:
Europe PubMed Central
Between 1997 and 2008, 97 adolescents and young adults with a median age 18.9 years (range, 15.0-33.6) with all stages Hodgkin's lymphoma (HL) were treated by a pediatric protocol DAL-HD-90m. The 12-year event-free survival and overall survival was 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3f1a051b537df8d9a6c9e613936e76de
http://europepmc.org/abstract/med/26995990
http://europepmc.org/abstract/med/26995990
Autor:
Vg, Savchenko, En, Parovichnikova, Bv, Afanas Ev, Sv, Gritsaev, Sergey Semochkin, Sn, Bondarenko, Vv, Troitskaia, An, Sokolov, La, Kuz Mina, Ga, Kliasova, Baranova OIu, Va, Lapin, Ts, Konstantinova, Os, Samoĭlova, Ts, Kaporskaia, Sv, Shatokhin
Publikováno v:
Europe PubMed Central
The purpose of the paper is to present Russian experts' consolidated opinion about acute myeloid leukemia (AML) treatment in adult patients aged less than 60 years. The guidelines have been elaborated having regard to foreign publications and Russian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e45caeb6a8c879fe708c844e788ffc33
http://europepmc.org/abstract/med/25314772
http://europepmc.org/abstract/med/25314772